Epigenetic-related therapeutic challenges in cardiovascular disease

Trends in Pharmacological Sciences

Volumn 36, Issue 4, 2015, Pages 226-235

  Schiano, Concetta ^a   Vietri, Maria Teresa ^b   Grimaldi, Vincenzo ^c   Picascia, Antonietta ^c   Pascale, Maria Rosaria De ^c   Napoli, Claudio ^a,c  

^a IRCCS SDN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

atherosclerosis; cardiovascular disease; cardiovascular pharmacology; epigenetics; natural compounds; statins

Indexed keywords

CARDIOVASCULAR AGENT; HISTONE; MICRORNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DNA METHYLATION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS;

EID: 84940005171     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.02.005     Document Type: Review

References (96)

1. C.L. Relton, and G. Davey Smith Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease Int. J. Epidemiol. 41 2012 161 176
2. B.E. Bernstein The mammalian epigenome Cell 128 2007 669 681
3. P.A. Jones Moving AHEAD with an international human epigenome project Nature 454 2008 711 715
4. A. Abbott Project set to map marks on genome Nature 463 2010 596 597
5. M.F. Fraga, and M. Esteller Towards the human cancer epigenome: a first draft of histone modifications Cell Cycle 4 2005 1377 1381
6. S. Udali Cardiovascular epigenetics: from DNA methylation to microRNAs Mol. Aspects Med. 34 2013 883 901
7. C. Schleithoff On the epigenetics of vascular regulation and disease Clin. Epigenetics 4 2012 7
8. A. Portela, and M. Esteller Epigenetic modifications and human disease Nat. Biotechnol. 28 2010 1057 1068
9. C. Napoli Maternal-foetal epigenetic interactions in the beginning of cardiovascular damage Cardiovasc. Res. 92 2011 367 374
10. D.E. Handy Epigenetic modifications: basic mechanisms and role in cardiovascular disease Circulation 123 2011 2145 2156
11. C. Napoli Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework Future Cardiol. 7 2011 485 497
12. C. Napoli Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms? Circulation 125 2012 2363 2373
13. R. Barrès Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density Cell Metab. 10 2009 189 198
14. B. Duygu Genetics and epigenetics of arrhythmia and heart failure Front. Genet. 4 2013 219
15. S.A. Mahmoud, and C. Poizat Epigenetics and chromatin remodelling in adult cardiomyopathy J. Pathol. 231 2013 147 157
16. G.H. Kim The role of redox signaling in epigenetics and cardiovascular disease Antioxid. Redox. Signal. 18 2013 1920 1936
17. J. Kim Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in vitro vascular senescence Biochim. Biophys. Acta 1772 2007 72 80
18. A. Horrillo Zebularine regulates early stages of mESC differentiation: effect on cardiac commitment Cell Death Dis. 4 2013 e570
19. J.J. Connelly Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis Hum. Mol. Genet. 22 2013 5107 5120
20. G. Arunachalam SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol Biochem. Biophys. Res. Commun. 393 2010 66 72
21. A. Crescenti Cocoa consumption alters the global DNA methylation of peripheral leukocytes in humans with cardiovascular disease risk factors: a randomized controlled trial PLoS ONE 8 2013 e65744
22. S.P. Guay Acetylsalicylic acid, aging and coronary artery disease are associated with ABCA1 DNA methylation in men Clin. Epigenetics 6 2014 14
23. S. Zaina A DNA methylation map of human atherosclerosis Circ. Cardiovasc. Genet. 7 2014 692 700
24. H.T. Yang Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials Eur. J. Intern. Med. 23 2012 745 754
25. F.H. Nazki Folate: metabolism, genes, polymorphisms and the associated diseases Gene 533 2014 11 20
26. M. Ciaccio, and C. Bellia Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction Curr. Clin. Pharmacol. 5 2010 30 36
27. E.R. Miller, and 3rd Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Am. J. Cardiol. 106 2010 517 527
28. F. Cacciapuoti Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties J. Thromb. Thrombolysis 32 2011 82 88
29. M.B. Glier Methyl nutrients, DNA methylation, and cardiovascular disease Mol. Nutr. Food Res. 58 2014 172 182
30. M.D. Jamaluddin Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene Blood 110 2007 3648 3655
31. M.O. Hiltunen, and S. Ylä-Herttuala DNA methylation, smooth muscle cells, and atherogenesis Arterioscler. Thromb. Vasc. Biol. 23 2003 1750 1753
32. F. Paneni Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective Atherosclerosis 230 2013 191 197
33. R. Feil, and M.F. Fraga Epigenetics and the environment: emerging patterns and implications Nat. Rev. Genet. 13 2012 97 109
34. K.B. Pandey, and S.I. Rizvi Plant polyphenols as dietary antioxidants in human health and disease Oxid. Med. Cell Longev. 2 2009 270 278
35. D.A. Parks, and F.M. Booyse Cardiovascular protection by alcohol and polyphenols - role of nitric oxide Ann. N. Y. Acad. Sci. 957 2002 115 121
36. M.H. Pan Epigenetic and disease targets by polyphenols Curr. Pharm. Des. 19 2013 6156 6185
37. W. Palinski, and C. Napoli Impaired fetal growth, cardiovascular disease, and the need to move on Circulation 117 2008 341 343
38. L. Verdone Role of histone acetylation in the control of gene expression Biochem. Cell. Biol. 83 2005 344 353
39. I. Garcia-Bassets Histone methylation dependent mechanisms impose ligand dependency for gene activation by nuclear receptors Cell 128 2007 505 518
40. L.A. Selth Transcript elongation by RNA polymerase II Annu. Rev. Biochem. 79 2010 271 293
41. C. Napoli Effects of nitric oxide on cell proliferation: novel insights J. Am. Coll. Cardiol. 62 2013 89 95
42. L.J. Ignarro Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview Circ. Res. 90 2002 21 28
43. J. Ho Nitric oxide signaling in hypoxia J. Mol. Med. 90 2012 217 231
44. J.R. Downs Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
45. J. Shepherd Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
46. P.O. Bonetti Statin effects beyond lipid lowering - are they clinically relevant? Eur. Heart J. 24 2003 225 248
47. C.M. Minder Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks Curr. Opin. Cardiol. 28 2013 554 560
48. P. Dje N'Guessan Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells Arterioscler. Thromb. Vasc. Biol. 29 2009 380 386
49. S. Han Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension Mol. Biol. Rep. 42 2015 35 42
50. W. Wongcharoen, and A. Phrommintikul The protective role of curcumin in cardiovascular diseases Int. J. Cardiol. 133 2009 145 151
51. K.B. Soni, and R. Kuttan Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers Indian J. Physiol. Pharmacol. 36 1992 273 275
52. A. Ramirez Boscá An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen Mech. Ageing Dev. 114 2000 207 210
53. T. Morimoto The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats J. Clin. Invest. 118 2008 868 878
54. L.X. Zhang Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs Am. J. Physiol. Cell. Physiol. 307 2014 C358 C372
55. A. Granger Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice FASEB J. 22 2008 3549 3560
56. L. Zhang Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis J. Pharmacol. Exp. Ther. 341 2012 285 293
57. M. Katoh Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks Int. J. Mol. Med. 32 2013 763 767
58. J.M. Churko Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases Circ. Res. 112 2013 1613 1623
59. J. Bauersachs, and T. Thum Biogenesis and regulation of cardiovascular microRNAs Circ. Res. 109 2011 334 347
60. E.M. Small MicroRNAs add a new dimension to cardiovascular disease Circulation 121 2010 1022 1032
61. M.V. Latronico, and G. Condorelli MicroRNAs and cardiac pathology Nat. Rev. Cardiol. 6 2009 419 429
62. C. Urbich Role of microRNAs in vascular diseases, inflammation, and angiogenesis Cardiovasc. Res. 79 2008 581 588
63. K.J. Rayner MiR-33 contributes to the regulation of cholesterol homeostasis Science 328 2010 1570 1573
64. J. Krützfeldt Silencing of microRNAs in vivo with 'antagomirs' Nature 438 2005 685 689
65. -/- mice J. Am. Heart Assoc. 1 2012 e003376
66. X. Loyer Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice Circ. Res. 114 2014 434 443
67. Y. Takahashi Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels Clin. Sci. (Lond.) 119 2010 395 405
68. V.G. Athyros Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease Curr. Pharm. Des. 20 2014 6299 6305
69. H.S. Soifer MicroRNAs in disease and potential therapeutic applications Mol. Ther. 15 2007 2070 2079
70. H.Y. Seok Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy Circ. Res. 114 2014 1585 1595
71. S.M. Welten Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia Circ. Res. 115 2014 696 708
72. E. van Rooij A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure Proc. Natl. Acad. Sci. U.S.A. 103 2006 18255 18260
73. Y. Zhao Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis Nature 436 2005 214 220
74. Y. Zhao Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2 Cell 129 2007 303 317
75. B. Yang The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 Nat. Med. 13 2007 486 491
76. L.P. Lim Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs Nature 433 2005 769 773
77. P.J. Batista Long noncoding RNAs: cellular address codes in development and disease Cell 152 2013 1298 1307
78. R. Papait Long noncoding RNA: a new player of heart failure? J. Cardiovasc. Transl. Res. 6 2013 876 883
79. L.M. Holdt ANRIL expression is associated with atherosclerosis risk at chromosome 9p21 Arterioscler. Thromb. Vasc. Biol. 30 2010 620 627
80. P. Grote The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse Dev. Cell 24 2013 206 214
81. C.A. Klattenhoff Braveheart, a long noncoding RNA required for cardiovascular lineage commitment Cell 152 2013 570 583
82. T.K. Kelly Epigenetic modifications as therapeutic targets Nat. Biotechnol. 28 2010 1069 1078
83. D. Pons Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease Eur. Heart J. 30 2009 266 277
84. C. Napoli The novel role of epigenetics in primary prevention of cardiovascular diseases Cardiogenetics 2 2012 e12
85. C. Napoli Unraveling framework of the ancestral mediator complex in human diseases Biochimie 94 2012 579 587
86. M.H. Kagey Mediator and cohesin connect gene expression and chromatin architecture Nature 467 2010 430 435
87. T. Tsutsui Mediator complex recruits epigenetic regulators via its two cyclin-dependent kinase subunits to repress transcription of immune response genes J. Biol. Chem. 288 2013 20955 20965
88. F. Lai Activating RNAs associate with mediator to enhance chromatin architecture and transcription Nature 494 2013 497 501
89. S. Borik Increased RNA editing in children with cyanotic congenital heart disease Intensive Care Med. 2011 1664e 1671e
90. M. Rienzo MED subunits: gene expression pattern, a novel transcript identification and nuclear localization in human endothelial progenitor cells Biochim. Biophys. Acta 1799 2010 487 495
91. M. Rienzo Distinct alternative splicing patterns of mediator subunit genes during endothelial progenitor cell differentiation Biochimie 94 2012 1828 1832
92. C. Napoli Endothelial progenitor cells as therapeutic agents in the microcirculation: an update Atherosclerosis 215 2011 9 22
93. A. Mattout, and E. Meshorer Chromatin plasticity and genome organization in pluripotent embryonic stem cells Curr. Opin. Cell Biol. 22 2010 334 341
94. A. Picascia Epigenetic control of autoimmune diseases: from bench to bedside Clin. Immunol. 157 2015 1 15
95. V. Grimaldi Epigenetic reprogramming in atherosclerosis Curr. Atheroscler. Rep. 17 2015 476
96. E. Meaburn, and R. Schulz Next generation sequencing in epigenetics: insights and challenges Semin. Cell Dev. Biol. 23 2012 192 199